Exact Sciences (NASDAQ:EXAS) Issues Earnings Results

Exact Sciences (NASDAQ:EXAS) released its quarterly earnings results on Wednesday. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23, Zacks reports. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Exact Sciences updated its FY 2025 guidance to EPS.

Exact Sciences Stock Performance

Shares of EXAS traded up $0.85 during trading hours on Wednesday, hitting $50.48. The stock had a trading volume of 3,321,382 shares, compared to its average volume of 2,211,632. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The firm has a 50-day moving average price of $55.66 and a 200 day moving average price of $60.17. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EXAS shares. Benchmark reissued a “buy” rating and set a $65.00 target price on shares of Exact Sciences in a research report on Monday, January 13th. Sanford C. Bernstein increased their price objective on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Evercore ISI dropped their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Jefferies Financial Group increased their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, TD Cowen raised their price target on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average target price of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.